X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Biosimilar User Fee Act (III) Performance Goals Letter will help increase options for patients and promote competition

By Richard Moscicki, M.D.  |    September 28, 2021
Last week, the U.S. Food and Drug Administration (FDA) released the Performance Goals Letter for the Biosimilar User Fee Act (BsUFA) III.   Read More

Meeting Tomorrow: Looking ahead to PDUFA VII

By Andrew Powaleny  |    September 27, 2021
Tomorrow, PhRMA will participate at the U.S. Food and Drug Administration’s (FDA) public meeting on the reauthorization of the Prescription Drug User Fee Act (PDUFA VII).   Read More

The impact of monoclonal antibodies and COVID-19 recovery

By Andrew Powaleny  |    September 2, 2021
As the United States and world continue to fight the COVID-19 pandemic, America’s biopharmaceutical research companies continue to do our part in fighting this deadly virus. Decades of scientific...   Read More

PDUFA VII is critical for future biopharmaceutical innovation and for patients

By Richard Moscicki, M.D.  |    August 23, 2021
Today, the U.S. Food and Drug Administration (FDA or Agency) released its performance goals letter for the seventh installment of the Prescription Drug User Fee Act (PDUFA).   Read More

How strengthening the biosimilar marketplace benefits patients

By Andrew Powaleny  |    May 18, 2021
Biologics are medicines that are made from living organisms through highly complex manufacturing processes and include a wide variety of medicines such as therapeutic proteins, monoclonal...   Read More

The FDA Office of Minority Health and Health Equity: Working to advance health equity through diversity in research

By Guest Contributor  |    May 12, 2021
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

2020 FDA approvals show innovation despite COVID-19 pandemic challenges

By Andrew Powaleny  |    January 26, 2021
A new report from the U.S. Food and Drug Administration (FDA) notes that the Center for Drug Evaluation and Research (CDER) approved 53 novel drugs last year. These figures are in addition to...   Read More

Nearly 400 cell and gene therapies in development to target a broad range of diseases

By Andrew Powaleny  |    March 10, 2020
In 2017, the U.S. approved its first cell and gene therapy, making the idea of altering a gene to cure or treat a disease a reality. As the increasing pace of R&D propels cell and gene therapy...   Read More

ICYMI: 2019 brings innovative medicines to patients

By Andrew Powaleny  |    January 17, 2020
New reports from the U.S. Food and Drug Administration (FDA) show a total of 55 novel new medicines were approved in 2019. Among these, 48 were approved by the Center for Drug Evaluation and...   Read More

PhRMA comments to Congress on Cures 2.0 call to action

By Anne McDonald Pritchett, PhD  |    December 18, 2019
As new therapies continue to revolutionize the treatment of many diseases, it is positive news that policymakers in Washington are discussing ways to ensure patient access to new treatments and...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates